Creo Medical Limited (CREO.L) Research

Creo Medical Limited, a UK-based enterprise and subsidiary of Creo Medical Group plc, specializes in the innovation and creation of electrosurgical medical devices for surgical endoscopy applications. Founded in 2003 as MicroOncology Ltd and headquartered in Chepstow, the company's core offering is Croma, an advanced energy platform. This platform is engineered to power a diverse collection of multi-modal instruments, thereby enhancing therapeutic interventions for both medical professionals and patients. Its extensive product portfolio includes specialized tools such as Speedboat Inject, an adaptable energy instrument designed for flexible endoscopic procedures; Speedboat Slim, a flexible bipolar radiofrequency (RF) and microwave device for precise tissue cutting and coagulation; MicroBlate Fine, a microwave needle for ablation; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device engineered to control upper and lower gastrointestinal bleeds; and SpydrBlade Flex, a flexible scissor-like instrument that integrates bipolar RF and microwave technology to grasp, cut, and coagulate highly vascularized tissues.

Market snapshot

Symbol
CREO.L
Price
$13.63
Day change
0.00%
Market cap
$61.2M
P/E ratio
10.64x
52-week range
9.52-18.5
Sector
Healthcare
Industry
Medical - Devices

Peer companies

  • AOTI, Inc. (AOTI.L)
  • Hemogenyx Pharmaceuticals Plc (HEMO.L)
  • hVIVO plc (HVO.L)
  • Inspiration Healthcare Group plc (IHC.L)
  • ImmuPharma plc (IMM.L)
  • Kooth plc (KOO.L)
  • Novacyt S.A. (NCYT.L)
  • Ondine Biomedical Inc. (OBI.L)

Open Creo Medical Limited (CREO.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.